Mainz Biomed (MYNZ) Competitors $3.22 +0.02 (+0.63%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.16 -0.06 (-1.71%) As of 04/17/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. PLUR, LEXX, GBIO, ATHE, CALC, CYTH, VYNE, KALA, TENX, and CLNNShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Pluri (PLUR), Lexaria Bioscience (LEXX), Generation Bio (GBIO), Alterity Therapeutics (ATHE), CalciMedica (CALC), Cyclo Therapeutics (CYTH), VYNE Therapeutics (VYNE), KALA BIO (KALA), Tenax Therapeutics (TENX), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Pluri Lexaria Bioscience Generation Bio Alterity Therapeutics CalciMedica Cyclo Therapeutics VYNE Therapeutics KALA BIO Tenax Therapeutics Clene Pluri (NASDAQ:PLUR) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Does the media prefer PLUR or MYNZ? In the previous week, Pluri had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Pluri and 1 mentions for Mainz Biomed. Pluri's average media sentiment score of 0.74 beat Mainz Biomed's score of -0.80 indicating that Pluri is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Is PLUR or MYNZ more profitable? Mainz Biomed has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Mainz Biomed's return on equity of 0.00% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-3,551.49% -2,778.13% -83.61% Mainz Biomed N/A N/A N/A Do analysts prefer PLUR or MYNZ? Mainz Biomed has a consensus target price of $14.00, suggesting a potential upside of 334.78%. Given Mainz Biomed's stronger consensus rating and higher possible upside, analysts clearly believe Mainz Biomed is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher earnings and valuation, PLUR or MYNZ? Pluri has higher earnings, but lower revenue than Mainz Biomed. Pluri is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$678K40.51-$20.89M-$5.60-0.70Mainz Biomed$893.99K8.35-$26.30M-$65.60-0.05 Do insiders & institutionals have more ownership in PLUR or MYNZ? 16.6% of Pluri shares are owned by institutional investors. 10.2% of Pluri shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in PLUR or MYNZ? Mainz Biomed received 14 more outperform votes than Pluri when rated by MarketBeat users. CompanyUnderperformOutperformPluriN/AN/AMainz BiomedOutperform Votes1473.68% Underperform Votes526.32% Which has more volatility and risk, PLUR or MYNZ? Pluri has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. SummaryMainz Biomed beats Pluri on 10 of the 17 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.47M$6.44B$5.30B$7.34BDividend YieldN/A3.21%5.45%4.30%P/E Ratio-0.056.8921.8617.80Price / Sales8.35230.51380.5997.73Price / CashN/A65.6738.2634.64Price / Book0.305.936.453.98Net Income-$26.30M$142.99M$3.22B$247.81M1 Month Performance-24.59%-13.57%-9.71%-7.84%1 Year Performance-91.10%-8.90%11.52%1.60% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed1.9197 of 5 stars$3.22+0.6%$14.00+334.8%-91.1%$7.47M$893,991.00-0.0530Positive NewsPLURPluri1.0523 of 5 stars$3.51-4.1%N/A-22.3%$24.80M$678,000.00-0.63150Short Interest ↓News CoverageGap DownLEXXLexaria Bioscience2.3234 of 5 stars$1.41flat$7.00+396.5%-38.7%$24.75M$496,923.00-2.827Earnings ReportShort Interest ↑Gap DownGBIOGeneration Bio2.7832 of 5 stars$0.37-1.5%$7.33+1,898.2%-86.0%$24.53M$19.89M-0.17150ATHEAlterity Therapeutics2.3487 of 5 stars$2.77-4.5%$12.00+333.2%+63.6%$24.47MN/A0.0010Short Interest ↓Positive NewsCALCCalciMedica1.5322 of 5 stars$1.81-0.8%$18.00+897.2%-61.4%$24.34MN/A-1.6730News CoverageCYTHCyclo Therapeutics2.769 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809VYNEVYNE Therapeutics2.9216 of 5 stars$1.52-2.6%$6.88+352.3%-19.6%$23.35M$501,000.00-1.7830KALAKALA BIO2.3034 of 5 stars$3.79-10.6%$15.00+295.6%-49.0%$23.30M$3.89M-0.3130TENXTenax Therapeutics2.0599 of 5 stars$5.75-0.9%$18.00+213.0%+47.0%$22.83MN/A-1.089CLNNClene2.7028 of 5 stars$2.65-1.5%$55.25+1,984.9%-54.5%$22.77M$342,000.00-0.50100Short Interest ↑ Related Companies and Tools Related Companies Pluri Alternatives Lexaria Bioscience Alternatives Generation Bio Alternatives Alterity Therapeutics Alternatives CalciMedica Alternatives Cyclo Therapeutics Alternatives VYNE Therapeutics Alternatives KALA BIO Alternatives Tenax Therapeutics Alternatives Clene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MYNZ Stock Free MYNZ Stock Alerts